Zoledronate to prevent bone loss in acute multiple sclerosis
A randomised controlled trial to evaluate whether zoledronate prevents bone loss in acute multiple sclerosis
What it found
The trial ended early for another reason (see below).
What was tested
Treatment tested
- Zoledronic acid anhydrous
What it measured
Main measures
A significant difference in serum type I collagen C-telopeptides (CTX) according to treatment group at day 7 of the study
Other measures (1)
Increased bone mineral density (BMD), measured at days 7, 90,180 and 360
Who could take part
MS (type not specified) · 18 and over
Show the full criteria
Inclusion criteria
Inclusion: 1. Aged 18 - 65 years (either sex) with a diagnosis of multiple sclerosis (MS) 2. Acute flare up requiring treatment with a corticosteroid 3. Able to attend for study investigations and assessments 4. Willing and able to provide informed consent Exclusion: 1. Previous diagnosis of osteoporosis 2. Bone therapy within previous 12 months 3. Previous bisphosphonate therapy at any time 4. Associated disorder that may affect bone metabolism 5. Pregnancy 6. Breastfeeding
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Not provided at time of registration
Loading reviews and guidelines…
History
Started
Apr 2009
Finished
Dec 2011